When your blood sugar is normal, it does not force your body to continuously pump out insulin
In the phase II ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16% (37 lbs) at the 240 mg dose at 44 weeks
In subsequent studies: PIONEER-6 and ELIXA the primary endpoints (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, hospitalization for unstable angina) were not met in the GLP-1 RAs group, but a significant decrease in glycated hemoglobin was observed
If you have hypothyroidism (low thyroid function) managed with levothyroxine, GLP-1 therapy is typically safebut weight loss may change your levothyroxine dose requirement
[DOI] [PMC free article] [PubMed] [Google Scholar] 253.Findley T., McEnroe K., Babuch G., Kim C., Broad Leib E